Lauren Cornell




Dr. Lauren Cornell is the co-founder and CEO of NovoThelium, a company focused on improving women’s health care, with a specific focus on modernizing nipple reconstruction post-mastectomy. Her company is developing nipple areolar grafts with the aim of giving women improved nipple projection.

Concurrently, Cornell is a researcher for the U.S. Air Force, contributing to the military branch’s mission to research, develop, and evaluate innovative technologies that impact the advancement of precision, regenerative, and diagnostic medicine for improving clinical outcomes for troops.

As a research scientist, Cornell has studied the genetics of human evolution, investigated carbon nanotubes for guided neuronal growth, and used magnetic nanoparticles to regenerate ocular tissue resulting from battlefield injuries. She conducted the latter research at the Sensory Trauma Department of the U.S. Army’s Institute of Surgical Research.

Cornell is a graduate of Texas A&M University, University of Texas at San Antonio, and University of Texas at Austin. She holds a Bachelor of Science in Genetics, a master’s degree in Biomedical Engineering, and a PhD in Translational Science, which is the process of turning research insights into commercial and public interventions.

She has served as a fellow at the Center for Drug Evaluation and Research at the Food and Drug Administration and has advocated to U.S. Congress for increased scientific funding for the National Institutes of Health, all while mentoring early-career scientists and entrepreneurs. In 2021, she was a crew member of Campaign 6 Mission 1 for the HERA Mars Analog at NASA Johnson Space Center.